DexCom, Inc. (DXCM)
NASDAQ: DXCM · IEX Real-Time Price · USD
125.88
-1.51 (-1.19%)
At close: May 1, 2024, 4:00 PM
126.29
+0.41 (0.33%)
Pre-market: May 2, 2024, 4:15 AM EDT
DexCom Revenue
DexCom had revenue of $3.80B in the twelve months ending March 31, 2024, with 25.78% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $921.00M with 24.21% year-over-year growth. In the year 2023, DexCom had annual revenue of $3.62B with 24.49% growth.
Revenue (ttm)
$3.80B
Revenue Growth
+25.78%
P/S Ratio
13.17
Revenue / Employee
$396,021
Employees
9,600
Market Cap
50.06B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3.62B | 712.50M | 24.49% |
Dec 31, 2022 | 2.91B | 461.30M | 18.84% |
Dec 31, 2021 | 2.45B | 521.80M | 27.08% |
Dec 31, 2020 | 1.93B | 450.70M | 30.54% |
Dec 31, 2019 | 1.48B | 444.40M | 43.08% |
Dec 31, 2018 | 1.03B | 313.10M | 43.58% |
Dec 31, 2017 | 718.50M | 145.20M | 25.33% |
Dec 31, 2016 | 573.30M | 171.30M | 42.61% |
Dec 31, 2015 | 402.00M | 142.80M | 55.09% |
Dec 31, 2014 | 259.20M | 99.20M | 62.00% |
Dec 31, 2013 | 160.00M | 60.10M | 60.16% |
Dec 31, 2012 | 99.90M | 23.60M | 30.93% |
Dec 31, 2011 | 76.30M | 27.70M | 57.00% |
Dec 31, 2010 | 48.60M | 18.91M | 63.67% |
Dec 31, 2009 | 29.69M | 19.86M | 201.82% |
Dec 31, 2008 | 9.84M | 5.21M | 112.62% |
Dec 31, 2007 | 4.63M | 2.46M | 113.23% |
Dec 31, 2006 | 2.17M | - | - |
Dec 31, 2005 | 0 | - | - |
Dec 31, 2004 | 0 | - | - |
Dec 31, 2003 | 0 | - | - |
Dec 31, 2002 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
McKesson | 301.51B |
Cencora | 271.58B |
Takeda Pharmaceutical | 29.40B |
Gilead Sciences | 27.12B |
Becton, Dickinson and Company | 19.49B |
IQVIA Holdings | 14.98B |
Zoetis | 8.54B |
Moderna | 6.85B |
DXCM News
- 6 days ago - Dexcom Reports First Quarter 2024 Financial Results - Business Wire
- 21 days ago - MD Revolution Partners with Dexcom to Integrate Continuous Glucose Monitoring Systems With its Remote Care Management Platform - Business Wire
- 21 days ago - This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives? - Market Watch
- 4 weeks ago - Dexcom Publishes Annual Sustainability Report - Business Wire
- 4 weeks ago - Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time - Business Wire
- 2 months ago - Dexcom announces its first ever over-the-counter CGM Stelo has been cleared by the FDA - CNBC
- 2 months ago - US FDA clears use of first over-the-counter continuous glucose monitor - Reuters
- 2 months ago - Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter - Business Wire